We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-0.01%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.89B
AUM Growth
-$643M
Cap. Flow
-$392M
Cap. Flow %
-5.69%
Top 10 Hldgs %
36.47%
Holding
178
New
7
Increased
49
Reduced
68
Closed
19

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$49.8M
2
ALGN icon
Align Technology
ALGN
+$27.1M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.9M
4
VEEV icon
Veeva Systems
VEEV
+$13.1M
5
LEGN icon
Legend Biotech
LEGN
+$7.46M

Top Sells

Rank Stock Value
1
MYOV
Myovant Sciences Ltd.
MYOV
+$159M
2
CI icon
Cigna
CI
+$30.6M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$27.6M
4
ELV icon
Elevance Health
ELV
+$26.9M
5
DXCM icon
DexCom
DXCM
+$26.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.07%
2 Industrials 0.84%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSTL icon
76
Castle Biosciences
CSTL
$733M
$21.6M 0.31%
948,878
+4,566
+0.5% +$112K
RMD icon
77
ResMed
RMD
$28.9B
$21.5M 0.31%
98,275
– –
BEAM icon
78
Beam Therapeutics
BEAM
$2.83B
$21.3M 0.31%
695,421
-1,300
-0.2% -$51.3K
PRCT icon
79
Procept Biorobotics
PRCT
$1.09B
$21.1M 0.31%
741,517
– –
PHR icon
80
Phreesia
PHR
$662M
$20.6M 0.3%
638,653
-27,766
-4% -$977K
HRMY icon
81
Harmony Biosciences
HRMY
$1.96B
$19.5M 0.28%
598,046
+1,854
+0.3% +$84.4K
WVE icon
82
Wave Life Sciences
WVE
$1.12B
$19.5M 0.28%
4,494,458
– –
TXG icon
83
10x Genomics
TXG
$5.55B
$18.1M 0.26%
324,746
– –
MRSN
84
DELISTED
Mersana Therapeutics
MRSN
$17.7M 0.26%
171,985
+681
+0.4% +$95.6K
SRRK icon
85
Scholar Rock
SRRK
$6.33B
$17.1M 0.25%
2,140,025
-12,000
-0.6% -$122K
GBIO
86
DELISTED
Generation Bio
GBIO
$15.6M 0.23%
362,028
-700
-0.2% -$33.9K
DOCS icon
87
Doximity
DOCS
$3.87B
$14.5M 0.21%
448,579
– –
CI icon
88
Cigna
CI
$74.5B
$13.7M 0.2%
53,476
-105,145
-66% -$30.6M
NTRA icon
89
Natera
NTRA
$38.9B
$12.9M 0.19%
232,775
+58,963
+34% +$2.83M
REGN icon
90
Regeneron Pharmaceuticals
REGN
$70.9B
$12.6M 0.18%
15,316
-362
-2% -$273K
ONC
91
BeOne Medicines Ltd
ONC
$32.4B
$12.6M 0.18%
58,235
+23,735
+69% +$5.69M
TDOC icon
92
Teladoc Health
TDOC
$1.7B
$11.2M 0.16%
432,721
+42,435
+11% +$1.14M
BAX icon
93
Baxter International
BAX
$11.7B
$11.1M 0.16%
273,614
-47,067
-15% -$2M
BDTX icon
94
Black Diamond Therapeutics
BDTX
$103M
$10.2M 0.15%
5,395,839
-5,000
-0.1% -$11.5K
AMGN icon
95
Amgen
AMGN
$198B
$9.28M 0.13%
38,367
-572
-1% -$140K
GILD icon
96
Gilead Sciences
GILD
$167B
$8.33M 0.12%
100,356
-29,987
-23% -$2.48M
NVRO
97
DELISTED
NEVRO CORP.
NVRO
$7.9M 0.11%
218,573
-42,262
-16% -$1.48M
BIIB icon
98
Biogen
BIIB
$30.4B
$6.87M 0.1%
24,704
-3,700
-13% -$1.02M
ESPR
99
DELISTED
Esperion Therapeutics
ESPR
$6.69M 0.1%
4,208,264
-122,000
-3% -$630K
RDY icon
100
Dr. Reddy's Laboratories
RDY
$10.5B
$5.89M 0.09%
517,500
-110,000
-18% -$1.19M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2023 Portfolio in Review

As of Q1 2023, Bellevue Group held 178 positions worth $6.89B, down 8.5% from $7.53B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group withdrew a net $392M in Q1 2023, closing 19 positions and reducing 68 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $159M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Verona Pharma worth $5.27M.

  • Bellevue Group's largest Q1 2023 buy was Verona Pharma: 262,683 shares worth $5.27M.
  • Bellevue Group added most to Medtronic in Q1 2023, an estimated $49.8M increase.
  • Bellevue Group's biggest Q1 2023 reduction was Cigna, cutting an estimated $30.6M.
  • Bellevue Group fully exited Myovant Sciences Ltd. in Q1 2023, selling an estimated $159M.
  • Bellevue Group's ten largest holdings make up 36% of its $6.89B portfolio in Q1 2023.
  • Bellevue Group opened 7 new positions and closed 19 in Q1 2023.
  • Bellevue Group's portfolio value fell 8.5% quarter-over-quarter to $6.89B.

Based on Bellevue Group's 13F filing for Q1 2023, filed 15 May 2023.